Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome Doug Brunk September 21, 2023 0 ...

InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release. The multinational, randomized, double-blind ...

"We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum. There are currently no ...

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum Provided by GlobeNewswire May 27, 2025, 10:30:00 PM ...

Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with the general population, according to a cohort study. “Pyoderma gangrenosum is a ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...

Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed A systematic review of 63 cases finds that pyoderma gangrenosum in pregnancy is frequently misdiagnosed.

SPOKANE, Wash. – Ryan Becker, a Spokane resident, is battling an extremely rare skin condition known as pyoderma gangrenosum. After visits to the Mayo Clinic and Johns Hopkins, Becker has been ...